| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/IJC.28047 |
| P698 | PubMed publication ID | 23335077 |
| P50 | author | Emmy Fleuren | Q57231770 |
| William Leenders | Q60537446 | ||
| Yvonne M H Versleijen-Jonkers | Q83069386 | ||
| P2093 | author name string | Otto C Boerman | |
| Winette T A van der Graaf | |||
| Myrella Vlenterie | |||
| Melissa H S Roeffen | |||
| Uta E Flucke | |||
| Hendrik W Schreuder | |||
| P2860 | cites work | Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer | Q27851588 |
| c-Met: structure, functions and potential for therapeutic inhibition | Q28190143 | ||
| Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines | Q28214508 | ||
| Targeting the c-Met signaling pathway in cancer | Q28246393 | ||
| Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system | Q28304840 | ||
| The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma | Q30494514 | ||
| Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data | Q33520467 | ||
| Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor | Q34172489 | ||
| The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma | Q34414730 | ||
| An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms | Q34625881 | ||
| Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. | Q34683782 | ||
| Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma | Q35108386 | ||
| VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer | Q35112894 | ||
| MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib | Q35666332 | ||
| Anaplastic lymphoma kinase proteins in growth control and cancer | Q35750450 | ||
| Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group | Q36389207 | ||
| Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer | Q36822111 | ||
| The anaplastic lymphoma kinase in the pathogenesis of cancer | Q37039605 | ||
| Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future | Q37182432 | ||
| Inhibition of ALK signaling for cancer therapy | Q37593792 | ||
| Targets for cancer therapy in childhood sarcomas | Q37707632 | ||
| Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications. | Q39673956 | ||
| Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients | Q39805159 | ||
| ALK (Anaplastic Lymphoma Kinase) expression in DRG neurons and its involvement in neuron-Schwann cells interaction. | Q39886471 | ||
| Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program | Q40009993 | ||
| Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program | Q40015224 | ||
| Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program | Q40141410 | ||
| MET overexpression turns human primary osteoblasts into osteosarcomas. | Q40285015 | ||
| Prognostic significance of c-Met expression in glioblastomas | Q46170165 | ||
| Expression of anaplastic lymphoma kinase in soft tissue tumors: an immunohistochemical and molecular study of 249 cases | Q47369102 | ||
| Angiogenic property of hepatocyte growth factor is dependent on upregulation of essential transcription factor for angiogenesis, ets-1. | Q48029331 | ||
| Expression of c-Met correlates with grade of malignancy in human astrocytic tumours: an immunohistochemical study | Q48571377 | ||
| Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. | Q54158447 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cabozantinib | Q795057 |
| P304 | page(s) | 427-436 | |
| P577 | publication date | 2013-02-25 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | Expression and clinical relevance of MET and ALK in Ewing sarcomas | |
| P478 | volume | 133 |
| Q50587004 | A preliminary study on a new model system to evaluate tumour-detection and tumour-purging protocols in ovarian cortex tissue intended for fertility preservation. |
| Q27310990 | ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors |
| Q34414378 | ALK-driven tumors and targeted therapy: focus on crizotinib |
| Q39780992 | Aminopyridyl/Pyrazinyl Spiro[indoline-3,4'-piperidine]-2-ones As Highly Selective and Efficacious c-Met/ALK Inhibitors |
| Q89803105 | Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial |
| Q89803112 | Cabozantinib: a new perspective for advanced bone sarcoma |
| Q91948077 | EWSR1/FUS-NFATc2 rearranged round cell sarcoma: clinicopathological series of 4 cases and literature review |
| Q38859977 | Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. |
| Q33875284 | Generation of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines |
| Q37385234 | High ALK mRNA expression has a negative prognostic significance in rhabdomyosarcoma. |
| Q38763225 | Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma |
| Q64114432 | Management of recurrent Ewing sarcoma: challenges and approaches |
| Q36250783 | Molecular profiling of childhood cancer: Biomarkers and novel therapies |
| Q47333317 | Pediatric Development of Molecularly Targeted Oncology Drugs |
| Q28082793 | Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers |
| Q38197031 | Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies |
| Q36527950 | Targeting protein kinases to reverse multidrug resistance in sarcoma. |
| Q35149569 | The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma |
| Q52655025 | The use of whole exome sequencing and murine patient derived xenografts as a method of chemosensitivity testing in sarcoma. |
| Q27693293 | Theranostic applications of antibodies in oncology. |
| Q52795602 | miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma. |
Search more.